October 1, 2020 07:29 AM EDTUpdated 11:05 AM

Covid-19 roundup: EMA starts rolling review of AstraZeneca vaccine; Novavax execs sell millions in stock ahead of PhIII

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Amber Tong

Though studies for the Covid-19 vaccine being developed by AstraZeneca and Oxford University researchers remain on hold in the US, Europe is speeding up its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: EMA starts rolling review of AstraZeneca vaccine; Novavax execs sell millions in stock ahead of PhIII

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: EMA starts rolling re­view of As­traZeneca vac­cine; No­vavax ex­ecs sell mil­lions in stock ahead of PhI­II

Editor

Senior Editor

Sign up to read this article for free.

Covid-19 roundup: EMA starts rolling review of AstraZeneca vaccine; Novavax execs sell millions in stock ahead of PhIII